Apollo Hospitals Enterprise Ltd(APOLLOHOSP)

NSE: APOLLOHOSPBSE: 508869

₹ 7,731.95+1.87%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 1.11 L crNext results: 4 Nov 2026Website: www.apollohospitals.comUpdated: 24 Oct 2026

About

Apollo Hospitals Enterprise Ltd is India's largest integrated healthcare group, operating tertiary and quaternary hospitals, a retail pharmacy chain, and a digital health platform. In FY26 the group reported consolidated revenue of ₹25,228.5 crore across three segments: Healthcare Services (50.1%), Digital Health & Pharmacy Distribution (42.5%), and Retail Health & Diagnostics (7.3%). Apollo Pharmacy runs 7,440 stores as of June 2026, making it one of India's largest pharmacy retail chains.^[1][2][3]

Business segments

Healthcare Services: 50.1% of FY26 revenue (₹12,750.1 crore), EBIT margin 19.1% - tertiary and quaternary hospital operations.^[2]
Digital Health & Pharmacy Distribution: 42.5% of FY26 revenue (₹10,808.1 crore), EBIT margin 3.7% - Apollo Pharmacy retail stores and Apollo 24|7 digital platform.^[2]
Retail Health & Diagnostics (AHLL): 7.3% of FY26 revenue (₹1,865.3 crore), EBIT margin 3.9% - diagnostics, clinics, and specialty day-care centres.^[2]

Hospital network and capacity

Total census bed capacity stood at 9,857 as of Q1 FY27, after commissioning 5 new hospitals (Pune, Sonarpur, Gachibowli, Defence Colony, Sarjapur-1) adding ~1,000 census beds.^[3]
Of the ~1,000 newly commissioned census beds, 380 have been operationalised; the remaining 620 beds are to be progressively activated over the next 12 - 18 months.^[3]
Long-range greenfield pipeline targets ~2,415 total beds (1,970 census) across Worli, Sarjapur-2, OMR Chennai, Varanasi, Lucknow and a Hyderabad Cancer Centre, targeted for FY29 - 30 at a project cost of ₹4,734 crore.^[4]
Total expansion pipeline project cost is ~₹11,150 crore, with a balance of ~₹7,500 crore remaining to be spent as of Q1 FY27.^[3]

Key operating metrics

ARPOB (Average Revenue per Occupied Bed) was ₹186,630 in Q1 FY27, up 8.3% YoY.^[3]
Overall bed occupancy reached 70% in Q1 FY27, up from 65% in Q1 FY26; established-unit occupancy reached 72% from 65%.^[3]
Inpatient discharges were 171,662 in Q1 FY27, up 13.3% YoY.^[3]
Average length of stay (inpatient) was 3.09 days in Q1 FY27, down 1.5% YoY.^[3]
Insurance and cash payors together accounted for 83% of inpatient hospital revenue in Q3 FY26.^[5]

Hospital profitability

Established-unit EBITDA margin reached 25.9% in Q1 FY27; overall Healthcare Services EBITDA margin was 24.2%, compressed 30 bps YoY by ₹375 mio of new-unit pre-operative losses.^[3]
Established-unit EBITDA margin was 25.5% in Q4 FY26, up 105 bps YoY from 24.4% in Q4 FY25.^[4]
CONGO-T specialties (cardiac, oncology, neurosciences, gastro, orthopaedics) delivered 16% revenue growth and 6% surgical volume growth YoY in Q3 FY26.^[5]
Transplant revenue grew ~50% quarter-on-quarter at the group level in Q3 FY26, supported by investment in robotics and digital command-centre technologies.^[5]

Pharmacy and digital health

Apollo Pharmacy operated 7,440 stores as of 30 June 2026, up from 7,289 stores at 31 March 2026 (net 668 additions in FY26).^[3][4]
Apollo 24|7 platform GMV was ₹5,351 mio in Q1 FY27, up 23% YoY; full-year FY26 GMV was ₹20,374 mio, up 24% YoY.^[3][4]
Digital cash loss narrowed to ₹97 mio in Q1 FY27, down ₹390 mio YoY; full-year FY26 digital cash loss was ₹1,329 mio, a 61% reduction from ₹3,373 mio in FY25.^[3][4]
Private label and generics accounted for 15.53% of total pharmacy sales in Q3 FY26.^[5]
Apollo HealthCo PAT rose 78% YoY to ₹1,013 mio in Q1 FY27.^[3]

Diagnostics and retail health (AHLL)

AHLL Diagnostics revenue grew 31% YoY and EBITDA grew 136% YoY in Q1 FY27; the Wellness segment grew ~38% and Specialty segment ~41% YoY, with ~50 new specialty tests added.^[3]
AHLL overall revenue grew 15% and EBITDA grew 46% YoY in Q1 FY27.^[3]

Expansion and corporate actions

Shareholders approved the NewCo composite scheme on 24 June 2026: the omnichannel pharmacy and Apollo 24|7 are to be demerged from Apollo Hospitals, and Apollo HealthCo and Keimed are to be amalgamated into a separately listed NewCo, targeting listing in Q4 FY27.^[3]
NewCo (Apollo HealthCo + Keimed) targets an annualised revenue run-rate of ₹250 bn in Q4 FY27 with an EBITDA margin of ~6.5 - 7.0%.^[3]
AHLL's Mother & Child and Fertility businesses are to combine with Cloudnine (subject to CCI approval); AHLL is valued at ₹1,550 crore via cash and a 9.9% equity stake in the combined entity.^[3][4]

Market Cap

₹1,11,174 Cr

High / Low

₹9,327 / 6,680

Stock P/E

53.2

Price / Book

11.7

Book Value

₹659

EPS

₹135.0

No. of Shares

14.38 Cr

ROCE

18.0%

ROE

21.9%

OPM

12.1%

Debt / Equity

0.60

Sales

₹25,229 Cr

Net Profit

₹2,003 Cr

Promoter holding

28.0%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials

Apollo Hospitals Enterprise Ltd(APOLLOHOSP)

About

Business segments

Hospital network and capacity

Key operating metrics

Hospital profitability

Pharmacy and digital health

Diagnostics and retail health (AHLL)

Expansion and corporate actions

Signal history

The analysis Screener can't give you

AI Deep Dive

Verdict

Company data

Product Segments

Corporate Actions